Dynavax Technologies Co. (NASDAQ:DVAX) VP David Louis Johnson sold 3,092 shares of Dynavax Technologies stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $18.60, for a total transaction of $57,511.20. Following the sale, the vice president now directly owns 7,780 shares of the company’s stock, valued at $144,708. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Dynavax Technologies Co. (NASDAQ:DVAX) traded down $0.30 during trading on Friday, reaching $15.75. 2,564,486 shares of the company’s stock traded hands, compared to its average volume of 1,350,000. The company has a market capitalization of $954.39, a P/E ratio of -8.04 and a beta of 1.31. Dynavax Technologies Co. has a 1-year low of $3.70 and a 1-year high of $24.45.
Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.15. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The firm’s revenue for the quarter was down 68.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.90) earnings per share. equities research analysts forecast that Dynavax Technologies Co. will post -1.72 EPS for the current year.
A number of institutional investors have recently bought and sold shares of DVAX. Russell Investments Group Ltd. lifted its stake in Dynavax Technologies by 24.0% in the second quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock worth $1,496,000 after purchasing an additional 30,036 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Dynavax Technologies by 77.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 181,161 shares of the biopharmaceutical company’s stock worth $1,749,000 after purchasing an additional 79,141 shares during the last quarter. Rhumbline Advisers lifted its stake in Dynavax Technologies by 35.5% in the second quarter. Rhumbline Advisers now owns 60,503 shares of the biopharmaceutical company’s stock worth $584,000 after purchasing an additional 15,865 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in Dynavax Technologies in the second quarter worth $328,000. Finally, Bank of New York Mellon Corp lifted its stake in Dynavax Technologies by 41.7% in the second quarter. Bank of New York Mellon Corp now owns 250,862 shares of the biopharmaceutical company’s stock worth $2,421,000 after purchasing an additional 73,866 shares during the last quarter. 70.54% of the stock is owned by institutional investors and hedge funds.
A number of analysts have recently issued reports on DVAX shares. Cantor Fitzgerald started coverage on shares of Dynavax Technologies in a report on Friday, September 15th. They set an “overweight” rating and a $24.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $28.00 price objective (up from $26.00) on shares of Dynavax Technologies in a report on Monday, September 25th. Cowen reaffirmed a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a report on Friday, November 3rd. ValuEngine downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BidaskClub downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Three analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $25.17.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/13/dynavax-technologies-co-dvax-vp-david-louis-johnson-sells-3092-shares.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.